KIMMTRAK is not an ACT but rather is a bi-specific T cell engager (TCE) protein that bridges T cells to tumor cells through a specific antibody domain that binds and activates CD3 on normal T cells of patients while it uses a melanoma-specific TCR binder recognizing gp100 that is highly expressed on metastatic uveal melanoma cells. Here, PMEL is linked to melanoma.